

INNOVA CAPTAB LIMITED  
1281/1, Hilltop Industrial Estate, Near  
EPIP, Phase-I, Jharmajri, Baddi, Dist.  
Solan (H.P.)-173205 India.  
Phone: +91-1795-650820



**May 19, 2025**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**BSE Symbol: INNOVACAP**  
**BSE Scrip Code: 544067**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5th Floor  
Plot No. C/1, “G” Block  
Bandra-Kurla Complex  
Bandra (E), Mumbai – 400 051  
**NSE Symbol: INNOVACAP**

Dear Sir/Madam,

**Subject: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2025.

The Press Release is available on the website of the Company at [www.innovacaptab.com](http://www.innovacaptab.com)

This is for your information and record.

Thanking you,

Yours faithfully,  
For **Innova Captab Limited**

**Neeharika Shukla**  
**Company Secretary & Compliance Officer**  
**Membership No.: A42724**

**Encl.: As above**

## **INNOVA CAPTAB LIMITED**

### **Press Release**

### **Performance Review of Q4 and FY25**

## **Innova Captab Limited reported healthy results for Q4 FY25, with Revenue from Operations at ₹ 314.7 crores and Profit After Tax (PAT) at ₹ 29.6 crores**

### **Registered YoY Revenue growth of 20% and PAT growth of 3%**

**Mumbai 19<sup>th</sup> May 2025:** Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading integrated pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter and financial year ending March 31<sup>st</sup>, 2025.

### **Key Highlights**

#### **Q4 FY25 vs Q4 FY24**

- Revenue from Operations registered robust growth of **20%**, reaching **₹ 314.7 crores** vs **₹ 262.6 crores** in Q4 FY24, driven by strong performance across all business areas
- Overall EBITDA registered stellar growth of **17%**, reaching **₹ 51.1 crores** vs **₹ 43.8 crores** in Q4 FY24. EBITDA margins were **16.2%**
- PAT rose by **3%** year-over-year to **₹ 29.6 crores** after absorbing the impact of depreciation and finance costs associated with Kathua, Jammu plant (commercialized in January 2025). PAT margins stood at **9.4%**

#### **FY25 vs FY24**

- Revenue from Operations grew **15%** to **₹ 1,243.7 crores** vs **₹ 1,081.3 crores** in FY24, led by volume growth across business areas
- EBITDA registered robust growth of **19%** to **₹ 198.2 crores** vs **₹ 166.9 crores** in FY24. EBITDA margin increased by **50 basis points** to **15.9%**
- PAT witnessed strong growth of **36%** to **₹ 128.3 crores** vs **₹ 94.3 crores** in FY24, driven by higher EBITDA and reduced finance costs. PAT margins improved by **160 basis points** to **10.3%**

Commenting on the results, **Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited** said **“We ended the year on a strong note, with all business areas performing in line with expectations. Strategic decisions taken over recent years are now delivering clear, measurable results—reflected in both our financial and operational performance. This momentum underscores the strength of our business model and the disciplined execution by our teams. We remain focused on our core priorities—growth, innovation, and customer-centricity—despite a dynamic and evolving market environment.**

**Operationally, we deepened our CDMO partnerships, broadened our product portfolio, expanded further in global markets, and strengthened our domestic reach. The commissioning of our Kathua, Jammu facility is a major milestone, enabling scaled production of new products and dosage forms—fueling our next growth phase.**

**All these enabled us to deliver stellar performance, and we closed the year at ₹ 1,243.7 crores, up 15% from last year. Profitability also improved with PAT increasing by 36% to ₹ 128.3 crores.**

**These achievements reaffirm our long-term strategy. With sharper focus, enhanced capacity, and strong execution, we are well-positioned to drive sustainable growth and create lasting value.”**

## **Financial Performance**

**(amount in ₹ crores except otherwise mentioned)**

### **Q4 FY25 vs Q4 FY24**

<b>Particulars</b>	<b>Q4 FY25</b>	<b>Q4 FY24</b>	<b>YoY Growth</b>
Revenue from Operations	<b>314.7</b>	<b>262.6</b>	<b>20%</b>
EBITDA	<b>51.1</b>	<b>43.8</b>	<b>17%</b>
EBITDA Margin (%)	<b>16.2%</b>	<b>16.7%</b>	<b>(50 bps)</b>
Profit after Tax	<b>29.6</b>	<b>28.7</b>	<b>3%</b>

### **FY25 vs FY24**

<b>Particulars</b>	<b>FY25</b>	<b>FY24</b>	<b>YoY Growth</b>
Revenue from Operations	<b>1,243.7</b>	<b>1,081.3</b>	<b>15%</b>
EBITDA	<b>198.2</b>	<b>166.9</b>	<b>19%</b>
EBITDA Margin (%)	<b>15.9%</b>	<b>15.4%</b>	<b>50 bps</b>
Profit after Tax	<b>128.3</b>	<b>94.3</b>	<b>36%</b>

## About Innova Captab Limited

*Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is an integrated pharmaceutical company in India with presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides over 3,300+ formulations to more than 200 pharmaceutical companies, including some of the largest ones in the Indian Pharmaceuticals Market. Innova's domestic branded generics business reaches 220,000 touchpoints, offering a diverse portfolio of over 750+ products. The company exports its finished formulations to 30 countries worldwide and operates five state-of-the-art manufacturing facilities, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA among others.*

*Innova expanded its capabilities with a greenfield project of a multi-dosage plant in Jammu, India which consists of 4 blocks – Cephalosporin, Penum, Penicillin and General. Together with this, the company now has total of 9 manufacturing blocks. Along with this, the company is also focussed on its R&D endeavours and is establishing a new R&D facility in Panchkula, Haryana in addition to the existing one in Baddi.*

*For more details, please visit [www.innovacaptab.com](http://www.innovacaptab.com)*

---

**For more information, please contact:**

**Mr. Lokesh Bhasin / Ayush Kumar Garg**

**Email: [investors@innovacaptab.com](mailto:investors@innovacaptab.com) / [ayush.garg@innovacaptab.com](mailto:ayush.garg@innovacaptab.com)**

### **DISCLAIMER:**

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.